ClinicalTrials.gg
RecruitingNCT07112872Updated Nov 12, 2026

A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes

A Phase 2 interventional study of Tifeglipron and Semaglutide in Type 2 Diabetes Mellitus, sponsored by Hoffmann-La Roche. Recruiting at 51 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Nov 12, 2026Now RecruitingSite recruiting status changed+9 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche — 7 open to participants now, 8 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Hoffmann-La Roche.

Planned enrollment
21st of 73
330 · median 196
Started
2025
with 2 others
Phase 2
23 of 73
2 open now
Registered
67th of 73
by date

Among the 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche, this one is the 21st largest by planned enrollment, is one of 3 that started in 2025, is one of 23 in phase 2, and was the 67th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of different doses of tifeglipron for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of Type 2 diabetes mellitus (T2D) for at least 6 months before screening
  • Have an ≥7% and ≤10.5% at screening
  • Management of T2D with diet and exercise alone or with either a stable dose of metformin or/and sodium-glucose cotransporter-2 (SGLT-2) inhibitors
  • (BMI) ≥23.0 kg/m\^2 at screening
  • A stable body weight within 3 months prior to screening (maximum 5% self-reported body weight gain and/or loss)

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 diabetes (T1D), history of ketosis or hyperosmolar state/coma, or any other types of diabetes except T2D
  • Have had 1 or more episodes of Level 3 hypoglycemia or has hypoglycemia unawareness within the 6 months prior to screening
  • History or presence of proliferative diabetic retinopathy, diabetic macular edema, or non-proliferative diabetic retinopathy that requires acute treatment
  • Evidence of /active nephropathy or neuropathy (including resting tachycardia, orthostatic hypotension, and diabetic diarrhea)
  • Current treatment or treatment within 3 months of screening with any other anti-hyperglycemic medication except metformin or SGLT-2 inhibitors
  • Have obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin-4 receptor deficiency or Prader-Willi Syndrome)
  • Have a known, clinically significant gastric emptying abnormality
  • Have poorly controlled hypertension at screening, untreated renal artery stenosis, or evidence of labile blood pressure including symptomatic postural hypotension
  • Have any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)/; Unstable angina; Hospitalization due to congestive heart failure
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
330 participants (estimated)

Study arms

  • Placebo comparator
    Part A, Arm 1: Placebo

    Drug: Placebo

  • Active comparator
    Part A, Arm 2: Semaglutide 14 mg

    Drug: Semaglutide

  • Experimental
    Part A, Arm 3: Tifeglipron Dosing Regimen 1

    Drug: Tifeglipron

  • Experimental
    Part A, Arm 4: Tifeglipron Dosing Regimen 2

    Drug: Tifeglipron

  • Experimental
    Part A, Arm 5: Tifeglipron Dosing Regimen 3

    Drug: Tifeglipron

  • Experimental
    Part A, Arm 6: Tifeglipron Dosing Regimen 4

    Drug: Tifeglipron

  • Experimental
    Part A, Arm 7: Tifeglipron Dosing Regimen 5

    Drug: Tifeglipron

  • Experimental
    Part A, Arm 8: Tifeglipron Dosing Regimen 6

    Drug: Tifeglipron

  • Experimental
    Part A, Arm 9: Tifeglipron Dosing Regimen 7

    Drug: Tifeglipron

  • Placebo comparator
    Part B, Arm 1: Placebo

    Drug: Placebo

  • Experimental
    Part B, Arm 2: Tifeglipron Dosing Regimen A

    Drug: Tifeglipron

  • Experimental
    Part B, Arm 3: Tifeglipron Dosing Regimen B

    Drug: Tifeglipron

Interventions

  • Tifeglipron will be taken orally once daily (QD), according to the randomized dosing regimen, during the 30-week treatment period.

    Also known as: RO7795081, CT-996, RG6652

  • Semaglutide 14 mg will be taken orally QD, with up-titration as per label, during the 30-week treatment period.

  • DrugPlacebo

    Placebo matching tifeglipron will be taken orally QD during the 30-week treatment period.

06

What researchers measure

Primary outcomes

  1. Tifeglipron vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30

    Time frame: Baseline to Week 30

Secondary outcomes

  1. Tifeglipron vs. Semaglutide (Part A): Change in HbA1c from Baseline at Week 30

    Time frame: Baseline to Week 30

  2. Percentage of Participants with HbA1c <5.7%, ≤6.5%, and <7.0% at Week 30

    Time frame: Week 30

  3. Change in Fasting Plasma Glucose from Baseline at Week 30

    Time frame: Baseline to Week 30

  4. Percent Change in Body Weight from Baseline at Week 30

    Time frame: Baseline to Week 30

  5. Absolute Change in Body Weight (kg) from Baseline at Week 30

    Time frame: Baseline to Week 30

  6. Percentage of Participants Who Achieve ≥5%, ≥10%, or ≥15% Body Weight Reduction from Baseline at Week 30

    Time frame: Baseline and Week 30

  7. Incidence of Adverse Events (AEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs)

    Time frame: From first dose until 28 days after the final dose of study treatment (34 weeks)

  8. Number of Participants with Documented Hypoglycemia (Level 1, 2, or 3 per American Diabetes Association 2025)

    Time frame: From first dose until 28 days after the final dose of study treatment (34 weeks)

  9. Plasma Concentrations of Tifeglipron at Prespecified Timepoints

    Time frame: Predose on Day 1 and at prespecified timepoints until Week 30

07

Study locations

10 of 51 sites recruiting
  • Arizona Liver Health - Tucson
    Tucson, Arizona 85712, United States
    Recruiting
  • Orange County Research Center
    Lake Forest, California 92630, United States
    Recruiting
  • Prospective Research Innovations Inc.
    Rancho Cucamonga, California 91730, United States
    Recruiting
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
    Recruiting
  • Chase Medical Research
    Waterbury, Connecticut 06708-3346, United States
    Recruiting
  • Emerson Clinical Research Institute
    Washington D.C., District of Columbia 20009, United States
    Recruiting
  • K2 Medical Research South Orlando, LLC
    Clermont, Florida 34711, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Center for Diabetes, Obesity and Metabolism Inc
    Pembroke Pines, Florida 33024, United States
    Completed

    Not enrolling at this site — choose another above.

  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Accellacare of Duly Health and Care
    Oak Lawn, Illinois 60453, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Mercury Street Medical Group, PLLC
    Butte, Montana 59701, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11516, United States
    Completed

    Not enrolling at this site — choose another above.

  • Accellacare of Piedmont Healthcare
    Statesville, North Carolina 28625, United States
    Recruiting
  • Accellacare of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
    Recruiting
  • NexGen Research
    Lima, Ohio 45801, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Tristar Clinical Investigations
    Philadelphia, Pennsylvania 19114, United States
    Recruiting
  • Alliance for Multispecialty Research. LLC
    Knoxville, Tennessee 37909, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Clinical Research Associates
    Nashville, Tennessee 37203, United States
    Completed

    Not enrolling at this site — choose another above.

  • Texas Diabetes & Endocrinology, P.A.
    Austin, Texas 78731, United States
    Completed

    Not enrolling at this site — choose another above.

  • Apex Mobile Clinical Research
    Bellaire, Texas 77401, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Velocity Clinical Research
    Dallas, Texas 75230, United States
    Completed

    Not enrolling at this site — choose another above.

  • Velocity Clinical Research (Impact Research Institute)
    Waco, Texas 76710, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Chrysalis Clinical Research
    St. George, Utah 84790, United States
    Completed

    Not enrolling at this site — choose another above.

  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
    Recruiting
  • Obudai Egeszsegugyi Centrum Kft.
    Budapest, 1036, Hungary
    Completed

    Not enrolling at this site — choose another above.

  • Qualiclinic Kft.
    Budapest, 1036, Hungary
    Withdrawn

    Not enrolling at this site — choose another above.

  • NZOZ Osteo-Medic s.c. A. Racewicz, J.Supronik
    Bialystok, Podlaskie Voivodeship 15-351, Poland
    Completed

    Not enrolling at this site — choose another above.

  • Centrum Badan Klinicznych PI-House sp. z o.o.
    Gdansk, Pomeranian Voivodeship 80-546, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centrum Medyczne INTERCOR Sp. z o.o.
    Bydgoszcz, 85-605, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Pro Familia Altera Sp z o.o.
    Katowice, 40-648, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • ETG Lublin
    Lublin, 20-412, Poland
    Completed

    Not enrolling at this site — choose another above.

  • Ekamed sp. z o.o.
    Lublin, 20-718, Poland
    Completed

    Not enrolling at this site — choose another above.

  • NZOZ METABOLICA Osrodek Badan Klinicznych
    Tarnów, 33-100, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • ETG Warszawa
    Warsaw, 02-677, Poland
    Completed

    Not enrolling at this site — choose another above.

  • Centrum Badan Klinicznych
    Wroclaw, 51-162, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • ETG Zamosc
    Zamość, 22-400, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universidad de Sevilla - Hospital Universitario Virgen Macarena
    Seville, Barcelona 41009, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Instituto De Investigacion Marques De Valdecilla (IDIVAL)
    Santander, Cantabria 39008, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Vithas Nisa Sevilla
    Castilleja de la Cuesta, Granada 41950, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitario A Coruna
    A Coruña, LA Coruna 15006, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Complexo Hospitalario Universitario de Ferrol (CHUF)
    Ferrol, LA Coruna 15405, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Regional Universitario de Malaga
    Malaga, Madrid 29011, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitario Virgen de la Victoria
    Málaga, Malaga 29010, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Centro Medico Teknon
    Barcelona, 08022, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Clinic de Barcelona (Hospital Clinic i Provincial)
    Barcelona, 08036, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital General Universitario Gregorio Maranon (HGUGM)
    Madrid, 28007, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitario Fundación Jimenez Díaz
    Madrid, 28040, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Nuevas Tecnologias en Diabetes y Endocrinologia
    Seville, 41003, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Quironsalud Infanta Luisa
    Seville, 41010, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Clinico Universitario de Valencia (Instituto de Investigacion Sanitaria INCLIVA)
    Valencia, 46010, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Feb 2028, 29 months after the start.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 29 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Nov 2026 → Feb 2028 and completion Nov 2026 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Aug 8, 2025
StartActual
Aug 19, 2025
Primary completionEst.
Feb 5, 2028was Nov 2026
CompletionEst.
Feb 5, 2028was Nov 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 12, 2026
Sites
6 sites added, 5 sites removed. 45 sites changed recruiting status (20 now active, not recruiting, 15 now completed, …)
Show 45 sites
  • Arizona Liver Health - Tucson · Tucson, United Statesno status→Recruiting
  • Orange County Research Center · Lake Forest, United Statesno status→Recruiting
  • Prospective Research Innovations Inc. · Rancho Cucamonga, United Statesno status→Recruiting
  • Encompass Clinical Research · Spring Valley, United Statesno status→Recruiting
  • Chase Medical Research · Waterbury, United Statesno status→Recruiting
  • Emerson Clinical Research Institute · Washington D.C., United Statesno status→Recruiting
  • K2 Medical Research South Orlando, LLC · Clermont, United Statesno status→Active, not recruiting
  • Center for Diabetes, Obesity and Metabolism Inc · Pembroke Pines, United Statesno status→Completed
  • Rophe Adult and Pediatric Medicine/SKYCRNG · Union City, United Statesno status→Active, not recruiting
  • Accellacare of Duly Health and Care · Oak Lawn, United Statesno status→Active, not recruiting
  • Neurobehavioral Research, Inc. · Cedarhurst, United Statesno status→Completed
  • Accellacare of Piedmont Healthcare · Statesville, United Statesno status→Recruiting
  • Accellacare of Wilmington, LLC · Wilmington, United Statesno status→Recruiting
  • NexGen Research · Lima, United Statesno status→Active, not recruiting
  • Tristar Clinical Investigations · Philadelphia, United Statesno status→Recruiting
  • Clinical Research Associates · Nashville, United Statesno status→Completed
  • Texas Diabetes & Endocrinology, P.A. · Austin, United Statesno status→Completed
  • Apex Mobile Clinical Research · Bellaire, United Statesno status→Active, not recruiting
  • Velocity Clinical Research · Dallas, United Statesno status→Completed
  • Chrysalis Clinical Research · St. George, United Statesno status→Completed
  • Manassas Clinical Research Center · Manassas, United Statesno status→Recruiting
  • Obudai Egeszsegugyi Centrum Kft. · Budapest, Hungaryno status→Completed
  • NZOZ Osteo-Medic s.c. A. Racewicz, J.Supronik · Bialystok, Polandno status→Completed
  • Centrum Badan Klinicznych PI-House sp. z o.o. · Gdansk, Polandno status→Active, not recruiting
  • Centrum Medyczne INTERCOR Sp. z o.o. · Bydgoszcz, Polandno status→Active, not recruiting
  • Pro Familia Altera Sp z o.o. · Katowice, Polandno status→Active, not recruiting
  • ETG Lublin · Lublin, Polandno status→Completed
  • Ekamed sp. z o.o. · Lublin, Polandno status→Completed
  • ETG Warszawa · Warsaw, Polandno status→Completed
  • Centrum Badan Klinicznych · Wroclaw, Polandno status→Active, not recruiting
  • …and 15 more on the registry record
Show 6 added (3 United States, 1 Hungary, 1 Poland, 1 Spain)
  • Mercury Street Medical Group, PLLC · Butte, United States
  • Alliance for Multispecialty Research. LLC · Knoxville, United States
  • Velocity Clinical Research (Impact Research Institute) · Waco, United States
  • Qualiclinic Kft. · Budapest, Hungary
  • NZOZ METABOLICA Osrodek Badan Klinicznych · Tarnów, Poland
  • Hospital Clinico Universitario de Valencia (Instituto de Investigacion Sanitaria INCLIVA) · Valencia, Spain
Show 5 removed
  • Mercury Street Medical Group, PLLC · Butte, United States
  • Alliance for Multispecialty Research. LLC · Knoxville, United States
  • Velocity Clinical Research (Impact Research Institute) · Waco, United States
  • Hospital Clinico Universitario de Valencia (Instituto de Investigacion Sanitaria INCLIVA) · Valencia, Spain
  • NZOZ METABOLICA O?rodek Bada? Klinicznych · Tarnów, Poland
across 2 updates, Oct 1, 2026 – Nov 12, 2026
Primary completion
Nov 27, 2026→Feb 5, 2028
Oct 1, 2026
Study completion
Nov 27, 2026→Feb 5, 2028
Oct 1, 2026
Enrollment
240→330
Oct 1, 2026
Interventions
Changed RO7795081→Tifeglipron. Arm changed Arm 1: Placebo→Part A, Arm 1: Placebo; Arm 2: Semaglutide 14 mg→Part A, Arm 2: Semaglutide 14 mg; Arm 3: RO7795081 Dosing Regimen 1→Part A, Arm 3: Tifeglipron Dosing Regimen 1; Arm 4: RO7795081 Dosing Regimen 2→Part A, Arm 4: Tifeglipron Dosing Regimen 2; Arm 5: RO7795081 Dosing Regimen 3→Part A, Arm 5: Tifeglipron Dosing Regimen 3; Arm 6: RO7795081 Dosing Regimen 4→Part A, Arm 6: Tifeglipron Dosing Regimen 4; Arm 7: RO7795081 Dosing Regimen 5→Part A, Arm 7: Tifeglipron Dosing Regimen 5; Arm 8: RO7795081 Dosing Regimen 6→Part A, Arm 8: Tifeglipron Dosing Regimen 6; Arm 9: RO7795081 Dosing Regimen 7→Part A, Arm 9: Tifeglipron Dosing Regimen 7; Part B, Arm 2: RO7795081 Dosing Regimen A→Part B, Arm 2: Tifeglipron Dosing Regimen A; Part B, Arm 3: RO7795081 Dosing Regimen B→Part B, Arm 3: Tifeglipron Dosing Regimen B. Arms added: Part B, Arm 1: Placebo·Part B, Arm 2: RO7795081 Dosing Regimen A·Part B, Arm 3: RO7795081 Dosing Regimen B
across 2 updates, Oct 1, 2026 – Nov 12, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedRO7795081Tifeglipron vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30Time frame: Baseline to Week 30
Nov 12, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 1, 2026
  • EditedRO7795081 vs. Semaglutide (Part A): Change in HbA1c from Baseline at Week 30Time frame: Baseline to Week 30
What changed on Nov 12, 2026
  • EditedRO7795081Tifeglipron vs. Semaglutide (Part A): Change in HbA1c from Baseline at Week 30Time frame: Baseline to Week 30
  • EditedPlasma Concentrations of RO7795081Tifeglipron at Prespecified TimepointsTime frame: Predose on Day 1 and at prespecified timepoints until Week 30
across 2 updates, Oct 1, 2026 – Nov 12, 2026
Contact
Study contact now listed: added g•••@gene.com · •••6728; added (no phone or email listed). See the current contact
Nov 12, 2026
Title
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes→A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
across 2 updates, Oct 1, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Active, not recruiting→Recruiting
    6 sites added, 1 site removed. 45 sites changed recruiting status (20 now active, not recruiting, 15 now completed, …)
    Show 45 sites
    • Arizona Liver Health - Tucson · Tucson, United Statesno status→Recruiting
    • Orange County Research Center · Lake Forest, United Statesno status→Recruiting
    • Prospective Research Innovations Inc. · Rancho Cucamonga, United Statesno status→Recruiting
    • Encompass Clinical Research · Spring Valley, United Statesno status→Recruiting
    • Chase Medical Research · Waterbury, United Statesno status→Recruiting
    • Emerson Clinical Research Institute · Washington D.C., United Statesno status→Recruiting
    • K2 Medical Research South Orlando, LLC · Clermont, United Statesno status→Active, not recruiting
    • Center for Diabetes, Obesity and Metabolism Inc · Pembroke Pines, United Statesno status→Completed
    • Rophe Adult and Pediatric Medicine/SKYCRNG · Union City, United Statesno status→Active, not recruiting
    • Accellacare of Duly Health and Care · Oak Lawn, United Statesno status→Active, not recruiting
    • Neurobehavioral Research, Inc. · Cedarhurst, United Statesno status→Completed
    • Accellacare of Piedmont Healthcare · Statesville, United Statesno status→Recruiting
    • Accellacare of Wilmington, LLC · Wilmington, United Statesno status→Recruiting
    • NexGen Research · Lima, United Statesno status→Active, not recruiting
    • Tristar Clinical Investigations · Philadelphia, United Statesno status→Recruiting
    • Clinical Research Associates · Nashville, United Statesno status→Completed
    • Texas Diabetes & Endocrinology, P.A. · Austin, United Statesno status→Completed
    • Apex Mobile Clinical Research · Bellaire, United Statesno status→Active, not recruiting
    • Velocity Clinical Research · Dallas, United Statesno status→Completed
    • Chrysalis Clinical Research · St. George, United Statesno status→Completed
    • Manassas Clinical Research Center · Manassas, United Statesno status→Recruiting
    • Obudai Egeszsegugyi Centrum Kft. · Budapest, Hungaryno status→Completed
    • NZOZ Osteo-Medic s.c. A. Racewicz, J.Supronik · Bialystok, Polandno status→Completed
    • Centrum Badan Klinicznych PI-House sp. z o.o. · Gdansk, Polandno status→Active, not recruiting
    • Centrum Medyczne INTERCOR Sp. z o.o. · Bydgoszcz, Polandno status→Active, not recruiting
    • Pro Familia Altera Sp z o.o. · Katowice, Polandno status→Active, not recruiting
    • ETG Lublin · Lublin, Polandno status→Completed
    • Ekamed sp. z o.o. · Lublin, Polandno status→Completed
    • ETG Warszawa · Warsaw, Polandno status→Completed
    • Centrum Badan Klinicznych · Wroclaw, Polandno status→Active, not recruiting
    • …and 15 more on the registry record
    Show 6 added (3 United States, 1 Hungary, 1 Poland, 1 Spain)
    • Mercury Street Medical Group, PLLC · Butte, United States
    • Alliance for Multispecialty Research. LLC · Knoxville, United States
    • Velocity Clinical Research (Impact Research Institute) · Waco, United States
    • Qualiclinic Kft. · Budapest, Hungary
    • NZOZ METABOLICA Osrodek Badan Klinicznych · Tarnów, Poland
    • Hospital Clinico Universitario de Valencia (Instituto de Investigacion Sanitaria INCLIVA) · Valencia, Spain
    Show 1 removed
    • NZOZ METABOLICA O?rodek Bada? Klinicznych · Tarnów, Poland
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedRO7795081Tifeglipron vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30Time frame: Baseline to Week 30
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedRO7795081Tifeglipron vs. Semaglutide (Part A): Change in HbA1c from Baseline at Week 30Time frame: Baseline to Week 30
    • EditedPlasma Concentrations of RO7795081Tifeglipron at Prespecified TimepointsTime frame: Predose on Day 1 and at prespecified timepoints until Week 30
    Interventions Changed RO7795081→Tifeglipron. Arm changed Part A, Arm 3: RO7795081 Dosing Regimen 1→Part A, Arm 3: Tifeglipron Dosing Regimen 1; Part A, Arm 4: RO7795081 Dosing Regimen 2→Part A, Arm 4: Tifeglipron Dosing Regimen 2; Part A, Arm 5: RO7795081 Dosing Regimen 3→Part A, Arm 5: Tifeglipron Dosing Regimen 3; Part A, Arm 6: RO7795081 Dosing Regimen 4→Part A, Arm 6: Tifeglipron Dosing Regimen 4; Part A, Arm 7: RO7795081 Dosing Regimen 5→Part A, Arm 7: Tifeglipron Dosing Regimen 5; Part A, Arm 8: RO7795081 Dosing Regimen 6→Part A, Arm 8: Tifeglipron Dosing Regimen 6; Part A, Arm 9: RO7795081 Dosing Regimen 7→Part A, Arm 9: Tifeglipron Dosing Regimen 7; Part B, Arm 2: RO7795081 Dosing Regimen A→Part B, Arm 2: Tifeglipron Dosing Regimen A; Part B, Arm 3: RO7795081 Dosing Regimen B→Part B, Arm 3: Tifeglipron Dosing Regimen B
    Contact Study contact now listed: added g•••@gene.com · •••6728; added (no phone or email listed). See the current contact
    Title A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
    + 2 other changes: verification date and description
  2. Oct 1, 2026
    4 sites removed
    Show 4 removed
    • Mercury Street Medical Group, PLLC · Butte, United States
    • Alliance for Multispecialty Research. LLC · Knoxville, United States
    • Velocity Clinical Research (Impact Research Institute) · Waco, United States
    • Hospital Clinico Universitario de Valencia (Instituto de Investigacion Sanitaria INCLIVA) · Valencia, Spain
    Primary completion Nov 27, 2026→Feb 5, 2028
    Study completion Nov 27, 2026→Feb 5, 2028
    Enrollment 240→330
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedRO7795081 vs. Semaglutide (Part A): Change in HbA1c from Baseline at Week 30Time frame: Baseline to Week 30
    Interventions Arm changed Arm 1: Placebo→Part A, Arm 1: Placebo; Arm 2: Semaglutide 14 mg→Part A, Arm 2: Semaglutide 14 mg; Arm 3: RO7795081 Dosing Regimen 1→Part A, Arm 3: RO7795081 Dosing Regimen 1; Arm 4: RO7795081 Dosing Regimen 2→Part A, Arm 4: RO7795081 Dosing Regimen 2; Arm 5: RO7795081 Dosing Regimen 3→Part A, Arm 5: RO7795081 Dosing Regimen 3; Arm 6: RO7795081 Dosing Regimen 4→Part A, Arm 6: RO7795081 Dosing Regimen 4; Arm 7: RO7795081 Dosing Regimen 5→Part A, Arm 7: RO7795081 Dosing Regimen 5; Arm 8: RO7795081 Dosing Regimen 6→Part A, Arm 8: RO7795081 Dosing Regimen 6; Arm 9: RO7795081 Dosing Regimen 7→Part A, Arm 9: RO7795081 Dosing Regimen 7. Arms added: Part B, Arm 1: Placebo·Part B, Arm 2: RO7795081 Dosing Regimen A·Part B, Arm 3: RO7795081 Dosing Regimen B
    Title A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
    + 3 other changes: verification date, description and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07112872
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Aug 19, 2025
Primary completion
Feb 5, 2028 (estimated)
Completion
Feb 5, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Reference Study ID Number: BP45703 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tifeglipron

Start the discussion